| [18] |
In vitro |
-
a)
2% and 3% (w/v) CS gel (Sigma-Aldrich, Germany) + 100 ng basic fibroblast growth factor (Sigma-Aldrich, Germany)
-
b)
2% and 3% (w/v) CS (Sigma-Aldrich, Germany) combined with 1.25% (w/v) hydroxyhapatite (BioRad, USA) + 100 ng basic fibroblast growth factor (Sigma-Aldrich, Germany)
-
c)
CS (Sigma-Aldrich, Germany) combined with 1.25% (w/v) hydroxyapatite (BioRad, USA)
-
d)
CS alone (Sigma-Aldrich, Germany)
|
MTT assay of CB and PDLCs (absorbance values, 570 nm) at day 8 and 7 respectively |
-
a)
PDLCs = 0.9; CB = 0.85
-
b)
PDLCs = 1; CB = 1.7
-
c)
PDLCs = 0.6; CB = 0.5
-
d)
PDLCs = O.6; CB = 0.6
|
| [20] |
In vitro |
-
a)
1.1% (w/v) CS (Sigma-Aldrich Germany) combined with 2% (w/v) alginate (Fluka AG, Germany) and 2% (w/v) PLGA (Sigma-Aldrich, Germany) + 100 ng IGF-1 (R&D, USA) and 25 ng BMP-6 (USCN, China)
-
b)
1.1% (w/v) CS (Sigma-Aldrich, Germany) combined with 2% (w/v) PLGA (Sigma-Aldrich, Germany) + 100 ng IGF-1 (R&D, USA) and 25 ng BMP-6 (USCN, China)
-
c)
CS (Sigma-Aldrich Germany) combined with alginate (Fluka AG, Germany)
-
d)
CS (Sigma-Aldrich Germany)
|
MTT assay of CB (absorbance values, 570 nm) at day 12 |
-
a)
CB = 2.6
-
b)
CB = 2.5
-
c)
CB = 2.4
-
d)
CB = 2
|
| [28] |
In vivo (left dorsal subcutaneous area in athymic mice) |
-
a)
CS (Sigma, St. Louis, MO, USA) dissolved in 2% acetic acid solution + β-tricalcium phosphate (Sigma–Aldrich Com) scaffold (mass ratio of β-tricalcium phosphate and CS = 3:7; total concentration = 1%)
-
b)
CS alone (Sigma, St. Louis, MO, USA)
|
MTT assay of PDLCs (absorbance values, 570 nm) at day 6 |
-
a)
PDLCs = 1
-
b)
PDLCs = 0.9
|
| [37] |
In vitro/in vivo (alveolar bone defects of mixed breed dogs) |
-
a)
CS solution (Sigma-Aldrich Chemical Co., St. Louis, MO, USA) and β-glycerolphosphate hydrogel (E. Merck, Darmstadt, Germany)
-
b)
CS powder and β-glycerolphosphate hydrogel (E. Merck, Darmstadt, Germany)
-
c)
Negative control
|
MTT assay of PDLCs (absorbance values, 490 nm) at day 6 |
-
a)
PDLCs = 0.7
-
b)
PDLCs = 0.6
-
c)
PDLCs = 0.65
|
